ELOQUENT-3 Trial: Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma Final Overall Survival Analysis

被引：0
|
作者：
Raab, Marc-Steffen [1 ]
Dimopoulos, Meletios [2 ]
Dytfeld, Dominik [3 ]
Grosicki, Sebastian [4 ]
Moreau, Philippe [5 ]
Takezako, Naoki [6 ]
Hori, Mitsuo [7 ]
Leleu, Xavier [8 ]
Leblanc, Richard [9 ]
Suzuki, Kenshi [10 ]
Richardson, Paul G. [11 ]
Mckiver, Mihaela Popa [12 ]
Jou, Ying-Ming [12 ]
Yao, David [12 ]
Das, Prianka [12 ]
San-Miguel, Jesus [13 ]
机构：
[1] Heidelberg Univ Hosp, Dept Med 5, Heidelberg, Germany
[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece
[3] Poznan Univ Med Sci, Dept Hematol & Bone Marrow Transplantat, Poznan, Poland
[4] Silesian Med Univ, Katowice, Poland
[5] Univ Hosp, Nantes, France
[6] Natl Hosp Org Disaster Med Ctr, Dept Hematol, Tokyo, Japan
[7] Ibaraki Cent Hosp, Dept Hematol, Kasama, Japan
[8] Ctr Hosp Univ Poitiers Miletrie, Poitiers, France
[9] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada
[10] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan
[11] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA
[12] Bristol Myers Squibb, Princeton, NJ USA
[13] Clin Univ Navarra CUUN, Inst Invest Sanitaria Navarra IDISNA, Ctr Invest Med Aplicada, Ctr Invest Biomed Red Canc CIBERONC, Pamplona, Spain
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
971
引用
收藏
页码：174 / 174
页数：1
相关论文
共 50 条
  • [31] CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
    Lonial, Sagar
    Richardson, Paul
    Reece, Donna
    Mohamed, Hesham
    Shelat, Suresh
    San Miguel, Jesus
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S330 - S330
  • [32] Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Paul G. Richardson
    Thierry Facon
    William I. Bensinger
    Xavier Leleu
    Frank Campana
    Sandrine Macé
    Marielle Chiron
    Helgi van de Velde
    Joseph Mikhael
    [J]. Blood Cancer Journal, 11
  • [33] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Dharshan Sivaraj
    Michael M Green
    Yubin Kang
    Gwynn D Long
    David A Rizzieri
    Zhiguo Li
    Anderson H Garrett
    Jackie L McIntyre
    Nelson J Chao
    Cristina Gasparetto
    [J]. Blood Cancer Journal, 8
  • [34] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Sivaraj, Dharshan
    Green, Michael M.
    Kang, Yubin
    Long, Gwynn D.
    Rizzieri, David A.
    Li, Zhiguo
    Garrett, Anderson H.
    McIntyre, Jackie L.
    Chao, Nelson J.
    Gasparetto, Cristina
    [J]. BLOOD CANCER JOURNAL, 2018, 8
  • [35] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] A phase 2 trial of leflunomide, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma
    Rosenzweig, Michael
    Sanchez, James
    Chowdhury, Arnab
    Nathwani, Nitya
    Janakiram, Murali
    Htut, Myo
    Sahebi, Firoozeh
    Walker, Tricia
    Pichiorri, Flavia
    Palmer, Joycelynne
    Krishnan, Amrita
    Keats, Jonathan
    Rosen, Steven
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S153 - S153
  • [37] Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Laplant, Betsy
    Alegria, Victoria R.
    Elliott, Jamie B.
    Sher, Taimur
    Paulus, Aneel
    Chapin, Dustin
    Heslop, Keisha
    Chanan-Khan, Asher
    Roy, Vivek
    [J]. BLOOD, 2022, 140 : 4450 - 4451
  • [38] Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone
    Morgan, Gareth
    Palumbo, Antonio
    Dhanasiri, Sujith
    Lee, Dawn
    Weisel, Katja
    Facon, Thierry
    Delforge, Michel
    Oriol, Albert
    Zaki, Mohamed
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Akehurst, Ron
    Offner, Fritz
    Dimopoulos, Meletios A.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (06) : 820 - 823
  • [39] Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (IKEMA): final overall survival analysis
    Yong, Kwee
    Martin, Thomas
    Dimopoulos, Meletios
    Mikhael, Joseph
    Capra, Marcelo
    Facon, Thierry
    Hajek, Roman
    Spicka, Ivan
    Baker, Ross
    Kim, Kihyun
    Martinez, Gracia
    Min, Chang-Ki
    Pour, Ludek
    Leleu, Xavier
    Oriol, Albert
    Koh, Youngil
    Suzuki, Kenshi
    Casca, France
    Mace, Sandrine
    Risse, Marie-Laure
    Moreau, Philippe
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S30 - S31
  • [40] Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma
    Weber, Donna
    Knight, Robert
    Chen, Christine
    Spencer, Andrew
    Yu, Zhinuan
    Zeldis, Jerome
    Olesnyckyj, Marta
    Dimopoulos, Meletios
    [J]. BLOOD, 2007, 110 (11) : 128A - 128A
12345